FY22 results point to progress across Tx and Dx

Lighthouse | 25 April 2023

Share this note

  • Avacta posted FY22 revenue of £9.65m (FY21: £2.94m), with a gross profit of £7.24m (FY21: £2.02m) and an operating loss of £32.65m (FY21: £29.08m). End-December 2022 cash resources were £41.78m and stood at c £39.0m at end-March 2023 following receipt of £2.8m in FY21 R&D tax credits. These resources provide ample funding to reach important value-inflection points within the Therapeutics pipeline and to explore further potential Diagnostics M&A opportunities.
  • Development progress continues across the Therapeutics business. Lead pre|CISION asset AVA6000, a tumour microenvironment activated form of doxorubicin, has successfully completed the fourth dose cohort of the Phase I trial with a favourable safety profile and a marked reduction in the incidence and severity of doxorubicin-associated toxicities. Post-period, the first patient was dosed in a fifth dose cohort. Data to date, including from tissue biopsies, confirm the release of active doxorubicin at the tumour site, with tumour drug levels materially higher than those in the bloodstream, confirming pre|CISION’s tumour targeting potential.
  • A second pre|CISION drug candidate, AVA3996, a tumour-targeted proteasome inhibitor, has shown in-vivo efficacy in multiple tumour models and is on track for an Investigational New Drug application in late 2023 to 2024. Key research partnerships with AffyXell (Daewoong Pharma) and LG Chem are also progressing, with receipt of a £3.6m milestone equity payment and a $2m licence renewal fee respectively.
  • The transformational acquisition of Launch Therapeutics for £24m in October 2022 was the first deal in the Diagnostics division’s ‘buy and build’ strategy to create a fully integrated in-vitro diagnostics (IVD) business (December 2022 Update). Avacta’s plan is to acquire complementary capabilities or products and expand geographically through M&A, while leveraging its internal expertise (ie the product development, regulatory, and compliance infrastructure established during the COVID pandemic) and its proprietary Affimer platform (to optimise product performance and economics).

Trinity Delta view: FY22 results reveal the financial, operational, and strategic progress made across both Avacta’s Therapeutics and Diagnostics divisions. The pre|CISION platform underpins the near- and medium-term prospects of its Therapeutics business, with emerging data from lead asset AVA6000 effectively validating the pre|CISION platform’s tumour targeting potential and providing the blueprint for an extensive pipeline of related products. AVA3996, the second pre|CISION asset, could enter the clinic within 12 months. The Diagnostics M&A-led growth strategy, seeded with the Launch Diagnostics acquisition, and complemented by internal capabilities and the proprietary Affimer platform, should create a self-sustaining Diagnostics business. Our current Avacta valuation is £587m, equivalent to 221p per share.


25 April 2023

Market Cap£352.2m
Primary exchangeAIM
Company CodeAVCT
Corporate clientYes

Company description

Avacta owns two novel technology platforms: Affimer and pre|CISION. Affimer proteins are antibody mimetics being developed as diagnostic reagents and oncology therapeutics. pre|CISION improves potency and reduces toxicity of cancer drugs by only activating them inside the tumour. Successful clinical trials would be transformative for Avacta.


Lala Gregorek
+44 (0) 20 3637 5043

Philippa Gardner
+44 (0) 20 3637 5042


Trinity Delta Research Limited (“TDRL”; firm reference number: 725161), which trades as Trinity Delta, is an appointed representative of Equity Development Limited (“ED”). The contents of this report, which has been prepared by and is the sole responsibility of TDRL, have been reviewed, but not independently verified, by ED which is authorised and regulated by the FCA, and whose reference number is 185325.

ED is acting for TDRL and not for any other person and will not be responsible for providing the protections provided to clients of TDRL nor for advising any other person in connection with the contents of this report and, except to the extent required by applicable law, including the rules of the FCA, owes no duty of care to any other such person. No reliance may be placed on ED for advice or recommendations with respect to the contents of this report and, to the extent it may do so under applicable law, ED makes no representation or warranty to the persons reading this report with regards to the information contained in it.

In the preparation of this report TDRL has used publicly available sources and taken reasonable efforts to ensure that the facts stated herein are clear, fair and not misleading, but make no guarantee or warranty as to the accuracy or completeness of the information or opinions contained herein, nor to provide updates should fresh information become available or opinions change.

Any person who is not a relevant person under section of Section 21(2) of the Financial Services & Markets Act 2000 of the United Kingdom should not act or rely on this document or any of its contents. Research on its client companies produced by TDRL is normally commissioned and paid for by those companies themselves (‘issuer financed research’) and as such is not deemed to be independent, as defined by the FCA, but is ‘objective’ in that the authors are stating their own opinions. The report should be considered a marketing communication for purposes of the FCA rules. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and it is not subject to any prohibition on dealing ahead of the dissemination of investment research. TDRL does not hold any positions in any of the companies mentioned in the report, although directors, employees or consultants of TDRL may hold positions in the companies mentioned. TDRL does impose restrictions on personal dealings. TDRL might also provide services to companies mentioned or solicit business from them.

This report is being provided to relevant persons to provide background information about the subject matter of the note. This document does not constitute, nor form part of, and should not be construed as, any offer for sale or purchase of (or solicitation of, or invitation to make any offer to buy or sell) any Securities (which may rise and fall in value). Nor shall it, or any part of it, form the basis of, or be relied on in connection with, any contract or commitment whatsoever. The information that we provide is not intended to be, and should not in any manner whatsoever be, construed as personalised advice. Self-certification by investors can be completed free of charge at www.fisma.org. TDRL, its affiliates, officers, directors and employees, and ED will not be liable for any loss or damage arising from any use of this document, to the maximum extent that the law permits.

Copyright 2023 Trinity Delta Research Limited. All rights reserved.